Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 7avelumab 6Nivolumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 4Biopsy 4Ipilimumab 3prednylidene 2lutetium Lu 177 dotatate 2deltacortene 2Radiosurgery 2Prednisone 2Immunoglobulin G 2Cyclophosphamide 2CTLA-4 Antigen 2talimogene laherparepvec 1sargramostim 1lenvatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1atezolizumab 1aldesleukin 1X-Rays 1Tacrolimus 1Sirolimus 1Saline Solution 1Radiotherapy 1MAPRE1 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Lidocaine, Prilocaine Drug Combination × 90 days × Clear all
NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
100 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡